Keep this leaflet. You may need to read it again. Prevenar 13 is a vaccine, which is a type of medicine that helps to protect (immunise) people from certain infectious diseases. It does this by ...

Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia ...

It covers 15 different pneumococcal serotypes – two more than Pfizer's current Prevnar 13 shot – and has been approved for use in patients aged 18 or over. Pfizer's updated 20-valent vaccine ...

PCV13, also known as Prevnar 13, was approved by the FDA in 2010 for children and 2011 for adults. Along with PCV7, the vaccine it replaced, PCV13 is no longer available. PCV21, also known as ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate ...

Results from a Phase II study completed in June 2023 showed that the vaccine had comparable immunogenicity to Prevnar 13, the control vaccine, after primary and booster vaccinations. The study ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

His roles included serving as Senior Vice President, Vaccine Research and Development, for Pfizer Inc., where he led the development of the Prevenar 13 vaccine for prevention of pneumococcal ...

making administration smoother compared to Prevnar 13. PAHO, a regional office for the Americas arm of the World Health Organization, views the importance of large-scale vaccine production and ...

See the full CMI for further details. PREVENAR 20 contains the active ingredient Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed). PREVENAR 20 is a vaccine, which is a type of ...